Pfizer sees potential 40% upside, despite institutional investment dip

Pfizer (NYSE:), a leading innovative biopharmaceutical company with over 150 years of history, has received an Equal-Weight recommendation from Wells Fargo, indicating a potential upside of 40.53%. The one-year price target averages at $45.12, with a range from $32.32 to $78.75. This comes as Pfizer’s annual revenue is projected to rise by 1.52% to $79,124MM, accompanied by a non-GAAP EPS of 5.02.

The company’s put/call ratio stands at 0.82, suggesting a bullish outlook despite a recent decrease in institutional investment. The number of funds or institutions invested in Pfizer has dropped by 3.77% to 4294 in the last quarter, and the average portfolio weight for PFE has decreased by 11.95% to 0.57%.

Wellington Management Group Llp and Capital World Investors remain key shareholders, holding 4.13% and 3.52% respectively. Wellington increased its holdings by 6.08%, while Capital World decreased its stake by 16.33%. Other significant shareholders include Vanguard Total Stock Market Index Fund Investor Shares (3.12%), Vanguard 500 Index Fund Investor Shares (2.38%), and Geode Capital Management (2%).

Pfizer continues to leverage science and global resources across developed and emerging markets to extend and significantly improve lives worldwide. It remains committed to challenging the most feared diseases and collaborates with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare.

The company routinely posts investor information on its website, reflecting its commitment to transparency in communication with stakeholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.